Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage chronic conditions such as diabetes and heart disease and others to help them lose weight
For weight management, NICE has approved semaglutide (Wegovy) for adults with specific BMI criteria (35 kg/m or 30 kg/m with weight-related comorbidities) within specialist weight management services
Kuo CY, Chiu YC, Lee AY, Hwang TL
Studies show patients with baseline metabolic assessments report better treatment alignment and side effect management compared to those without pre-treatment evaluation
Foundational factors still matter Even if peptides increase anabolic signaling, they will not build muscle without: Progressive resistance training Adequate protein intake Sufficient sleep Caloric surplus when bulking No peptide replaces consistency
Falutz J et al., "Metabolic effects of a growth hormone-releasing factor in patients with HIV," New England Journal of Medicine, 2007
